ITACA-S study was designed to evaluate whether a sequential treatment of FOLFIRI [ irinotecan plus 5-fluorouracil/folinic acid ( 5-FU/LV ) ] followed by docetaxel plus cisplatin improves disease-free survival in comparison with 5-FU/LV in patients with radically resected gastric cancer .